SuperworthGinkgo Bioworks EPS DNA
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Dec 31, 2025
- −$5.65
- Latest quarter, Q4 FY25
- −$1.42
- Fiscal year 2025
- −$5.65
Ginkgo Bioworks' earnings per share was −$5.65 over the twelve months to Dec 31, 2025.
In its latest quarter, Q4 FY25, it was −$1.42.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$5.65 | n/a |
| FY2024 | −$10.63 | n/a |
| FY2023 | −$18.49 | n/a |
| FY2022 | −$51.20 | n/a |
| FY2021 | −$49.20 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY25 | −$1.42 | n/a | −$5.65 | |
| Q3 FY25 | −$1.45 | n/a | −$6.23 | |
| Q2 FY25 | −$1.10 | n/a | −$5.86 | |
| Q1 FY25 | −$1.68 | n/a | −$8.99 | |
| Q4 FY24 | −$2.00 | n/a | −$10.63 | |
| Q3 FY24 | −$1.08 | n/a | −$12.91 | |
| Q2 FY24 | −$4.23 | n/a | −$18.04 | |
| Q1 FY24 | −$3.32 | n/a | −$17.41 | |
| Q4 FY23 | −$4.28 | n/a | −$18.49 | |
| Q3 FY23 | −$6.21 | n/a | −$17.81 | |
| Q2 FY23 | −$3.60 | n/a | −$28.00 | |
| Q1 FY23 | −$4.40 | n/a | −$40.80 |
Against its peers
Companies in Biotechnology nearest Ginkgo Bioworks' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DNAGinkgo Bioworks | n/m | |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ginkgo Bioworks
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.